The move from big pharma to stem cells is underway as Shire makes a $200M deal to purchase Pervasis

FierceBiotech recently reported that Shire is buying the biotech Pervasis Therapeutics with an eye toward boosting its regenerative medicine unit, adding the small company’s cellular therapy in mid-stage development for vascular repair in patients on hemodialysis. The buyout follows Shire’s purchase of Advanced BioHealing last year in a deal that created the business that specializes in cell-based therapies.

Ireland-based Shire didn’t disclose the exact deal terms in its announcement, but the deal could be worth up to $200 million, with the majority of the deal’s value linked to the future success of Pervasis’ programs in clinical trials and on the market, Jessica Mann, head of global corporate communications at Shire, told FierceBiotech.

Read the full article to find out what is acquisition will mean for the industry.

To understand different types of stem cells, the mode of action of stem cells and impact of recent advances on the commercial market join us for the 3 Day MBA course in Stem Cells